Straits Times Index
3,212.64 -6.36 (-0.20%) Nikkei
27,385.25 -34.36 (-0.13%) Hang Seng
19,915.68 -133.96 (-0.67%) FTSE 100
7,381.53 -118.07 (-1.57%) Bitcoin USD
27,998.26 -723.51 (-2.52%) CMC Crypto 200
608.68 -9.71 (-1.57%)
BCRX Jan 2024 8.000 call
| Previous close | 2.0000 |
| Open | 1.9000 |
| Bid | 1.8000 |
| Ask | 2.6500 |
| Strike | 8.00 |
| Expiry date | 2024-01-19 |
| Day's range | 1.9000 - 1.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.4k |
- Motley Fool
Why Shares of BioCryst Pharmaceuticals Jumped Today
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) were up 12% Wednesday afternoon, a day after the commercial-stage biotech released full-year and fourth-quarter earnings. The stock dropped as much as 17.1% on Tuesday after the earnings report, but Wednesday, it bounced back as much as 14% over the day before. Needham upgraded the stock to "buy" from "hold," adding a $14 price target, and H.C. Wainwright analyst Andrew Fein set a price target of $30 on the stock and reiterated his buy rating.
- Motley Fool
Why BioCryst Pharmaceuticals Stock Is Sinking Today
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) are sinking today, down by 17.1% as of 11:09 a.m. ET. The big decline came after the drugmaker announced its fourth-quarter and full-year 2022 results before the market opened. BioCryst reported Q4 revenue of $79.5 million, up from $47.2 million in the prior-year period.
- Motley Fool
BioCryst Pharmaceuticals (BCRX) Q4 2022 Earnings Call Transcript
Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; chief commercial officer, Charlie Gayer; and chief R&D officer, Dr. 2022 was another outstanding year for ORLADEYO as we doubled sales in our second full year of launch on top of the fantastic start we had in the first year.
